| Issue Date | Title | Author(s) |
| 2023 | Association of GDF15 levels with body mass index and endocrine status in β-Thalassaemia | Karusheva, Y.; Petry, C.J.; Yasara, N.; Kottahachchi, D.; Premawardhena, A.; Barker, P.; Burling, K.; Sattar, N.; Welsh, P.; Mettananda, S.; O'Rahilly, S.S. |
| 2021 | A Comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic | Yasara, N.; Premawardhena, A.; Mettananda, S. |
| 2023 | Direct correction of haemoglobin E β-thalassaemia using base editors | Badat, M.; Ejaz, A.; Hua, P.; Rice, S.; Zhang, W.; Hentges, L.D.; Fisher, C.A.; Denny, N.; Schwessinger, R.; Yasara, N.; Roy, N.B.A.; Issa, F.; Roy, A.; Telfer, P.; Hughes, J.; Mettananda, S.; Higgs, D.R.; Davies, J.O.J. |
| 2020 | Efficacy and Safety of Oral Hydroxyurea in Patients with Transfusion Dependent β Thalassaemia: a Randomized Double-Blind Placebo-Controlled Clinical Trial | Yasara, N.; Wickramarathne, N.; Silva, I.; Hameed, N.; Attanayaka, A.M.K.R.; Jayasinghe, V.L.; Wickramasinghe, N.; Rodrigo, R.; Perera, L.; Mettananda, K.C.D.; Manamperi, A.; Premawardhena, A.; Mettananda, S. |
| 2020 | Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial | Yasara, N.; Wickramarathne, N.; Mettananda, C.; Manamperi, A.; Premawardhena, A.; Mettananda, S. |
| 2021 | Efficacy of hydroxyurea in reducing the erythropoietic stress of ineffective erythropoiesis in transfusion dependent beta thalassaemia: A randomised, double-blind placebo-controlled clinical trial | Yasara, N.; Premawardhena, A.; Perera, P.; Manamperi, A.; Mettananda, S. |
| 2022 | Electronic screen device usage and screen time among preschool-attending children in a suburban area of Sri Lanka | Rathnasiri, A.; Rathnayaka, H.; Yasara, N.; Mettananda, S. |
| 2024 | GDF15 linked to maternal risk of nausea and vomiting during pregnancy | Fejzo, M.; Rocha, N.; Cimino, I.; Lockhart, S.M.; Petry, C.J.; Kay, R.G.; Burling, K.; Barker, P.; George, A.L.; Yasara, N.; Premawardhena, A.; Gong, S.; Cook, E.; Rimmington, D.; Rainbow, K.; Withers, D.J.; Cortessis, V.; Mullin, P.M.; MacGibbon, K.W.; Jin, E.; Kam, A.; Campbell, A.; Polasek, O.; Tzoneva, G.; Gribble, F.M.; Yeo, G.S.H.; Lam, B.Y.H.; Saudek, V.; Hughes, I.A.; Ong, K.K.; Perry, J.R.B.; Sutton, C.A.; Baumgarten, M.; Welsh, P.; Sattar, N.; Smith, G.C.S.; Charnock- Jones, D.S.; Coll, A.P.; Meek, C.L.; Mettananda, S.; Hayward, C.; Mancuso, N.; O'Rahilly, S. |
| 2021 | Hydroxyurea for transfusion dependent β-thalassaemia: A randomized double-blind placebo-controlled clinical trial | Yasara, N.; Wickramarathne, N.; Silva, I.; Hameed, N.; Attanayaka, A.M.K.R.; Jayasinghe, V.L.; Gunathilaka, P.A.C.K.; Wickramasinghe, N.; Rodrigo, R.; Perera, L; Perera, P.S.; Mettananda, K.C.D.; Manamperi, A.; Premawardhena, A.; Mettananda, S. |
| 2021 | In vitro study to identify effects of fetal haemoglobin inducing agents on primary human erythroid cells | Yasara, N.; Manamperi, A.; Mettananda, S. |
| 2022 | A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia | Yasara, N.; Wickramarathne, N.; Mettananda, C.; Silva, I.; Hameed, N.; Attanayaka, K.; Rodrigo, R.; Wickramasinghe, N.; Perera, L.; Manamperi, A.; Premawardhena, A.; Mettananda, S. |
| 2019 | Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemia | Mettananda, S.; Yasara, N.; Fisher, C. A.; Taylor, S.; Gibbons, R.; Higgs, D. |
